Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | TNB-486 |
| Trade Name | |
| Synonyms | TNB486|TNB 486|AZD0486|AZD-0486|AZD 0486|Surovatamig |
| Drug Descriptions |
TNB-486 is a bispecific T-cell redirecting antibody that binds to CD19 on tumor cells as well as CD3, and may lead to tumor cell killing and inhibition of tumor growth (Blood (2019) 134 (Supplement_1): 4070). |
| DrugClasses | CD19 Antibody 21 CD3 Antibody 119 |
| CAS Registry Number | NA |
| NCIT ID | C178577 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Acalabrutinib + TNB-486 | Acalabrutinib TNB-486 | 0 | 1 |
| Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + TNB-486 + Vincristine Sulfate | Cyclophosphamide Doxorubicin Prednisone Rituximab TNB-486 Vincristine Sulfate | 0 | 2 |
| Rituximab + TNB-486 | Rituximab TNB-486 | 0 | 1 |
| TNB-486 | TNB-486 | 0 | 4 |